Fischer G W, Hemming V G, Hunter K W, Gloser H, Bachmayer H, Von Pilar C E, Helting T, Weisman L E, Wilson S R, Baron P A
Pediatr Infect Dis. 1986 May-Jun;5(3 Suppl):S171-5.
IGIV appears to have a promising future in treating and perhaps preventing neonatal bacterial infections. However, all IGIV lots do not contain equal amounts of pathogen-specific IgG with functional opsonic activity. To ensure effective therapy it will be important to inform physicians that the IGIV lots available for use contain functional antibacterial antibody to the responsible pathogens. To optimize therapy IGIV may need to be given early in the infection and doses may need to be repeated if pathogen-specific antibody is rapidly depleted. Further, clinical studies will be necessary to determine if IGIV will be a valuable adjunct to antibiotic therapy in neonatal GBS infections.
静脉注射免疫球蛋白（IGIV）在治疗甚至预防新生儿细菌感染方面似乎有着光明的前景。然而，并非所有批次的IGIV都含有等量具有功能性调理活性的病原体特异性IgG。为确保治疗有效，告知医生可用的IGIV批次含有针对相关病原体的功能性抗菌抗体非常重要。为优化治疗，可能需要在感染早期给予IGIV，并且如果病原体特异性抗体迅速消耗，可能需要重复给药。此外，有必要进行临床研究以确定IGIV在新生儿B族链球菌感染中是否会成为抗生素治疗的有价值辅助手段。
